The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Thrombolytic therapy for pulmonary embolism
Open accessAbstract
BACKGROUND: Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. This is the fourth update of the Cochrane review first published in 2006. OBJECTIVES: To assess the effects of thrombolytic therapy for acute pulmonary embolism. SEARCH METHODS: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 17 August 2020. We undertook reference checking to identify additional studies. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared thrombolytic therapy followed by heparin versus heparin alone, heparin plus placebo, or surgical intervention for people with acute PE (massive/submassive). We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug. DATA COLLECTION AND ANALYSIS: Two review authors (ZZ, QH) assessed the eligibility and risk of bias of trials and extracted data. We calculated effect estimates using the odds ratio (OR) with a 95% confidence interval (CI) or the mean difference (MD) with a 95% CI. The primary outcomes of interest were death, recurrence of PE and haemorrhagic events. We assessed the certainty of the evidence using GRADE criteria. MAIN RESULTS: We identified three new studies for inclusion in this update. We included 21 trials in the review, with a total of 2401 participants. No studies compared thrombolytics versus surgical intervention. We were not able to include one study in the meta-analysis because it provided no extractable data. Most studies carried a high or unclear risk of bias related to randomisation and blinding. Meta-analysis showed that, compared to control (heparin alone or heparin plus placebo), thrombolytics plus heparin probably reduce both the odds of death (OR 0.58, 95% CI 0.38 to 0.88; 19 studies, 2319 participants; low-certainty evidence), and recurrence of PE (OR 0.54, 95% CI 0.32 to 0.91; 12 studies, 2050 participants; low-certainty evidence). Effects on mortality weakened when six studies at high risk of bias were excluded from analysis (OR 0.71, 95% CI 0.45 to 1.13; 13 studies, 2046 participants) and in the analysis of submassive PE participants (OR 0.61, 95% CI 0.37 to 1.02; 1993 participants). Effects on recurrence of PE also weakened after removing one study at high risk of bias for sensitivity analysis (OR 0.60, 95% CI 0.35 to 1.04; 11 studies, 1949 participants). We downgraded the certainty of evidence to low because of 'Risk of bias' concerns. Major haemorrhagic events were probably more common in the thrombolytics group than in the control group (OR 2.84, 95% CI 1.92 to 4.20; 15 studies, 2101 participants; moderate-certainty evidence), as were minor haemorrhagic events (OR 2.97, 95% CI 1.66 to 5.30; 13 studies,1757 participants; low-certainty evidence). We downgraded the certainty of the evidence to moderate or low because of 'Risk of bias' concerns and inconsistency. Haemorrhagic stroke may occur more often in the thrombolytics group than in the control group (OR 7.59, 95% CI 1.38 to 41.72; 2 studies, 1091 participants). Limited data indicated that thrombolytics may benefit haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment, echocardiograms, pulmonary hypertension, coagulation parameters, composite clinical outcomes, need for escalation and survival time to a greater extent than heparin alone. However, the heterogeneity of the studies and the small number of participants involved warrant caution when interpreting results. The length of hospital stay was shorter in the thrombolytics group than in the control group (mean difference (MD) -1.40 days, 95% CI -2.69 to -0.11; 5 studies, 368 participants). Haemodynamic decompensation may occur less in the thrombolytics group than in the control group (OR 0.36, 95% CI 0.20 to 0.66; 3 studies, 1157 participants). Quality of life was similar between the two treatment groups. None of the included studies provided data on post-thrombotic syndrome or on cost comparison. AUTHORS' CONCLUSIONS: Low-certainty evidence suggests that thrombolytics may reduce death following acute pulmonary embolism compared with heparin (the effectiveness was mainly driven by one trial with massive PE). Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause more major and minor haemorrhagic events, including haemorrhagic stroke. More studies of high methodological quality are needed to assess safety and cost effectiveness of thrombolytic th
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kucher, N., Boekstegers, P., Müller, O. J., Kupatt, C., Beyer-Westendorf, J., Heitzer, T., Tebbe, U., Horstkotte, J., Müller, R., Blessing, E., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005544 · Cited by 1,151
Research works printed but not linked: 68
- Dalla-Volta, 1992, PAIMS2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2, Journal of the American College of Cardiology, 20, 520, 10.1016/0735-1097(92)90002-5 · DOI · Paper page
- Goldhaber, 1993, Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion, The Lancet, 341, 507, 10.1016/0140-6736(93)90274-K · DOI · Paper page
- Konstantinides, 2002, Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism, New England Journal of Medicine, 347, 1143, 10.1056/NEJMoa021274 · DOI · Paper page
- Levine, 1990, A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism, Chest, 98, 1473, 10.1378/chest.98.6.1473 · DOI · Paper page
- Ly, 1978, A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism, Acta Medica Scandinavica, 203, 465, 10.1111/j.0954-6820.1978.tb14909.x · DOI · Paper page
- Anonymous, 1990, Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators, Chest, 97, 528, 10.1378/chest.97.3.528 · DOI · Paper page
- Tibbutt, 1974, Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism, British Medical Journal, 1, 343, 10.1136/bmj.1.5904.343 · DOI · Paper page
- Anonymous, 1970, Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study, JAMA, 214, 2163, 10.1001/jama.1970.03180120035007 · DOI · Paper page
- Sasahara, 1973, The urokinase pulmonary embolism trial, Circulation, 47, 7
- Agnelli, 1997, Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group, Blood Coagulation & Fibrinolysis, 8, 216, 10.1097/00001721-199706000-00002 · doi:10.1097/00001721-199706000-00002
- Anonymous, 1984, Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism, Archives des Maladies du Coeur et des Vaisseaux, 77, 773
- Bell, 1974, The urokinase-streptokinase pulmonary embolism trial (phase II) results, Circulation, 50, 1070, 10.1161/01.CIR.50.6.1070 · DOI
- Bell, 1976, Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study, Thrombosis and Haemostasis, 35, 57, 10.1055/s-0038-1647911 · doi:10.1055/s-0038-1647911
- Bell, 1977, Thrombolytic therapy: differences between streptokinase and urokinase, Vascular Surgery, 11, 378, 10.1177/153857447701100607 · doi:10.1177/153857447701100607
- Takats, 1973, The urokinase pulmonary embolism trial, American Journal of Surgery, 126, 311, 10.1016/S0002-9610(73)80114-X · doi:10.1016/s0002-9610(73)80114-x
- Dotter, 1979, Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison, Vascular Surgery, 13, 42, 10.1177/153857447901300107 · DOI
- Erkan L Findik S Atici AG Uzun O Thrombolytic therapy in massive pulmonary thromboembolism European Respiratory Journal 2002 237s
- Francois, 1986, Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. 67 cases, Archives des Maladies du Coeur et des Vaisseaux, 79, 435
- Goldhaber, 1989, Tissue plasminogen activator in acute pulmonary embolism, Chest, 95, 282S, 10.1378/chest.95.5_Supplement.282S · doi:10.1378/chest.95.5_supplement.282s
- Goldhaber, 1989, TPA versus urokinase in acute pulmonary embolism: Results of a randomized controlled trial, Vasa - Supplementum, 27, 292
- Goldhaber, 1992, Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial, Journal of the American College of Cardiology, 20, 24, 10.1016/0735-1097(92)90132-7 · DOI · Paper page
- Goldhaber, 1994, Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: An international multicenter randomised trial, Chest, 106, 718, 10.1378/chest.106.3.718 · DOI · Paper page
- Jerjes-Sanchez, 1995, Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial, Journal of Thrombosis & Thrombolysis, 2, 227, 10.1007/BF01062714 · DOI · Paper page
- Konstantinides, 1998, Comparison of alteplase versus heparin for resolution of major pulmonary embolism, American Journal of Cardiology, 82, 966, 10.1016/S0002-9149(98)00513-X · DOI · Paper page
- Marder, 1978, Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism, Journal of Laboratory Clinical Medicine, 92, 721
- Giuntini, 1984, A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism, Giornale Italiano di Cardiologia, 14 Suppl 1, 26
- Marini, 1988, Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial, Respiration, 54, 162, 10.1159/000195517 · DOI
- Meneveau, 1997, Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction, European Heart Journal, 18, 1141, 10.1093/oxfordjournals.eurheartj.a015410 · DOI
- Meneveau, 1998, Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up, Journal of the American College of Cardiology, 31, 1057, 10.1016/S0735-1097(98)00068-0 · DOI · Paper page
- Meyer, 1992, Comparison of the effect of an intravenous infusion of urokinase or alteplase on total pulmonary resistance in acute massive pulmonary embolism. A European, multi-center, double-blind study, Intensivmedizin und Notfallmedizin, 29, 339
- Meyer, 1992, Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism, Journal of the American College of Cardiology, 19, 239, 10.1016/0735-1097(92)90472-Y · DOI · Paper page
- Miller, 1971, Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism, British Medical Journal, 763, 681, 10.1136/bmj.2.5763.681 · DOI · Paper page
- Muhl, 2007, Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism, Blood Coagulation & Fibrinolysis, 18, 661, 10.1097/MBC.0b013e3282e38e61 · DOI
- Ohayon, 1986, Hemodynamic course during fibrinolysis in severe pulmonary embolism, Archives des Maladies du Coeur et des Vaisseaux, 79, 445
- Palla, 1997, Resolution of pulmonary embolism: effect of therapy and putative age of emboli, Respiration, 64, 50, 10.1159/000196642 · doi:10.1159/000196642
- Pang, 2007, [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism], Zhonghua yi xue za zhi, 87, 3074
- Prandoni, 1985, Diagnostic approaches and results in the medical treatment of pulmonary thromboembolism, Minerva Medica, 76, 1727
- Saponjski, 2002, Massive pulmonary embolism and thrombolysis in the first week after major surgery, European Respiratory Journal, 20, 239s
- Sasahara, 1975, The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study, Thrombosis et Diathesis Haemorrhagica, 33, 464
- Sharma, 1980, Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism, New England Journal of Medicine, 303, 842, 10.1056/NEJM198010093031502 · DOI · Paper page
- Sharma, 2000, Long-term benefit of thrombolytic therapy in patients with pulmonary embolism, Vascular Medicine, 5, 91, 10.1177/1358836X0000500205 · DOI
- Sors, 1994, Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial, Chest, 106, 712, 10.1378/chest.106.3.712 · DOI · Paper page
- Tebbe, 1999, Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism, American Heart Journal, 138, 39, 10.1016/S0002-8703(99)70243-7 · DOI
- 1974, Urokinase Streptokinase Embolism Trial. Phase II results, JAMA : the journal of the American Medical Association, 229, 1606, 10.1001/jama.1974.03230500024021 · DOI · Paper page
- 1987, The UKEP Study: multicentre clinical trial on two local regimes of urokinase in massive pulmonary embolism, European Heart Journal, 8, 2, 10.1093/oxfordjournals.eurheartj.a062154 · doi:10.1093/oxfordjournals.eurheartj.a062154
- Verstraete, 1988, Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism, Circulation, 77, 353, 10.1161/01.CIR.77.2.353 · DOI · Paper page
- Wang, 2006, [The clinical features of 516 patients with acute pulmonary thromboembolism], Zhonghua yi xue za zhi, 86, 2161
- Yang, 2007, Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism [Abstract], European Respiratory Journal, 30, 544s
- Bottiger, 1994, Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism, Resuscitation, 28, 45, 10.1016/0300-9572(94)90054-X · doi:10.1016/0300-9572(94)90054-x
- Browse, 1962, Streptokinase and pulmonary embolism, Lancet, 2, 1039
- Chesterman, 1969, Streptokinase therapy in acute major pulmonary embolism, Medical Journal of Australia, 2, 1096, 10.5694/j.1326-5377.1969.tb107628.x · doi:10.5694/j.1326-5377.1969.tb107628.x
- Genton, 1968, Urokinase therapy in pulmonary thromboembolism, American Heart Journal, 76, 628, 10.1016/0002-8703(68)90161-0 · doi:10.1016/0002-8703(68)90161-0
- Goldhaber, 1988, Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism, Lancet, 2, 293, 10.1016/S0140-6736(88)92354-9 · DOI · Paper page
- Higgins, 2008, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
- Hirsh, 1971, Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism, Canadian Medical Association Journal, 104, 488
- Hyers, 1970, Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1), Circulation, 42, 979, 10.1161/01.CIR.42.6.979 · doi:10.1161/01.cir.42.6.979
- Konstantinides, 1999, Submassive and massive pulmonary embolism: a target for thrombolytic therapy?, Thrombosis and Haemostasis, 82, 104
- Perlroth, 2007, Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism, Archives of Internal Medicine, 167, 74, 10.1001/archinte.167.1.74 · DOI
- Sasahara, 1967, Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent, New England Journal of Medicine, 277, 1168, 10.1056/NEJM196711302772203 · doi:10.1056/nejm196711302772203
- Sasahara, 1973, The urokinase pulmonary embolism trial: A national cooperative study, Circulation, 47, 7
- Sautter, 1967, Urokinase for the treatment of acute pulmonary thromboembolism, JAMA, 202, 215, 10.1001/jama.1967.03130160089019 · doi:10.1001/jama.1967.03130160089019
- Serra-Prat, 1999, Efficacy and safety of thrombolytic therapy in pulmonary embolism: meta-analysis of randomized controlled trials, Medicina Clinica, 112, 685
- Stein, 1990, Tissue plasminogen activator for the treatment of acute pulmonary embolism, Chest, 97, 52833
- Tow, 1967, Urokinase in pulmonary embolism, New England Journal of Medicine, 277, 1161, 10.1056/NEJM196711302772202 · DOI
- Vander Sande, 1988, Thrombolytic treatment of pulmonary embolism with APSAC, European Respiratory Journal, 1, 721, 10.1183/09031936.93.01080721 · doi:10.1183/09031936.93.01080721
- Wu, 2007, The concepts, design, practice and reports of allocation concealment and blinding, Chinese Journal of Evidence-Based Medicine, 7, 222
- Yamasawa, 1992, The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism, Internal Medicine, 31, 885, 10.2169/internalmedicine.31.885 · doi:10.2169/internalmedicine.31.885
- Dong, 2006, Thrombolytic therapy for pulmonary embolism, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004437.pub2 · doi:10.1002/14651858.cd004437.pub2
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Chatterjee, S., Chakraborty, A., Weinberg, I., Kadakia, M., Wilensky, R. L., Sardar, P., Kumbhani, D. J., Mukherjee, D., Jaff, M. R., & Giri, J. (2014) · JAMA · doi:10.1001/jama.2014.5990 · Cited by 818
Metadata
- Authors
- Dong, B. R., Hao, Q., Yue, J., Wu, T., & Liu, G. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2009-07-08
- Volume
- 4
- Issue
- 3
- Pages
- CD004437-CD004437
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2105077761
- Cited by
- 174
- References
- 1
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2015-09-30)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombolytic therapy for pulmonary embolism. https://app.cochat.ai/papers/10.1002/14651858.cd004437.pub3
- The paper
- Dong, B. R., Hao, Q., Yue, J., Wu, T., & Liu, G. J. (2009). Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004437.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.